Abstract 343P
Background
Palonosetron was greater than first-generation 5-HT3 receptor antagonists in the prevention of nausea and vomiting have been established in many systematic reviews. However, several recent randomized control trials manifested inconsistent results. Thus, we conducted a systematic review to evaluate the efficacy and safety of palonosetron versus granisetron in chemotherapy induced nausea and vomiting (CINV).
Methods
The PubMed, Embase, and The Cochrane Library databases were searched for studies published before April 2020. The meta-analysis was performed to estimate the pooled effect sizes by using a random effect model. The primary outcome was treatment responses of CINV (complete response rate, complete control rate, and total control rate). Secondary outcomes were 5-HT3 receptor antagonist related common side effects (constipation, and headache).
Results
Twelve randomized controlled trials, three prospective studies and one retrospective study were reviewed. Palonosetron was consistently statistically superior in any phase of complete response rate (acute phases: odds ratio [OR]= 1.37, 95% confidence interval [CI]: 1.03 to 1.82; delayed phases: OR= 1.57, 95% CI: 1.15 to 2.15; overall phases: OR= 1.37, 95% CI: 1.17 to 1.60), delayed phases of complete control rate and total control rate (OR= 1.45, 95% CI: 1.23 to 1.72; OR= 1.29, 95% CI: 1.01 to 1.65, respectively). Subgroup analysis indicated that there was no significant difference between palonosetron and granisetron in any phase of complete response when combined with NK1 antagonists. No statistically significant difference was found between constipation and diarrhea toxicities of the two groups.
Conclusions
Although palonosetron significantly decreased the risk of chemotherapy induced nausea and vomiting in any phase, granisetron is seeming comparable effectiveness with palonosetron when adding NK1 antagonists.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
338P - Vitamin E in the treatment of chemotherapy and radiation-induced mucositis: A meta-analysis of randomized controlled trials
Presenter: Michelle Joane Alcantara
Session: e-Poster Display Session
339P - Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation: A phase III study
Presenter: Vikas Talreja
Session: e-Poster Display Session
340P - Omega-3 fatty acids for cancer cachexia in advanced non-small cell lung cancer: A meta-analysis
Presenter: Alfredo Chua
Session: e-Poster Display Session
341P - Relationship between muscle mass and quality of life in breast cancer patients who underwent chemotherapy
Presenter: Andree Kurniawan
Session: e-Poster Display Session
342P - Comparison of 0.25 mg versus 0.75 mg of palonosetron in combination with aprepitant and dexamethasone for prevention of chemotherapy-induced nausea and vomiting following cisplatin-containing chemotherapy in patients with esophageal cancer
Presenter: Satoshi Horasawa
Session: e-Poster Display Session
344P - Single-centre analysis of anti-resorptive agent-related osteonecrosis of the jaw in lung cancer patients
Presenter: Kohei Fujita
Session: e-Poster Display Session
345P - Thromboembolic events in brain tumour patients on bevacizumab
Presenter: Gunjesh Singh
Session: e-Poster Display Session
346P - Occurence and risk factors of chemotherapy-induced neutropenia in patients with breast cancer: A hospital-based assessment in Indonesia
Presenter: Susanna Hutajulu
Session: e-Poster Display Session
347P - Histamine blockade with loratadine for prevention of granulocyte-colony stimulating factor (G-CSF)-associated bone pain: A meta-analysis
Presenter: Mel Valerie Ordinario
Session: e-Poster Display Session
348P - Anti-VEGF inhibitors and renal safety in onco-nephrology consortium: Urinary protein/creatinine ratio (VERSiON UP study)
Presenter: Michio Nakamura
Session: e-Poster Display Session